Drug pricing malpractice
Careful analysis of the seemingly intractable problem of rising medical costs can typically be reduced to three things: 1) who pays? (the accustomed answer generally being “someone else”); 2) the creeping role of the federal government in making that determination; and 3) the parasitic, and growing, impact of litigation. The back-and-forth over the 340B drug […]
Original Source
Read the full article at Washingtonexaminer →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.